(Boursier.com) — The Group Equasens recorded an increase in its turnover as of June 30, 2023 of 8.7% compared to the first half of 2022 at €112.6 million. The Group’s Current Operating Income increased by 6.9% to €27.5 million as of June 30, 2023. The Net Income stood at €22.9 million (+9.2%) and the Group’s share of Net Income was 22 ME (+11.4%).
As of June 30, 2023, the Basic Earnings per Share amounts to 1.46 euros compared to 1.31 euros as of June 30, 2022 (+11.2%).
The cash flows generated over the period were particularly favorable and allowed a notable increase in the gross cash position (145.4 ME and +26.2 ME compared to 12/31/2022).
With a net financial surplus of €77.2 million, the Group maintains strong autonomy and significant investment capacity. Shareholders’ equity, group share, amounts to €194.7 million as of 06/30/2023.
Outlook for the 2nd half of 2023
The Equasens Group is approaching the 2nd half of 2023 with confidence. At this stage, excluding exceptional events, the Group maintains its growth forecasts for the year 2023.
The integration of recent acquisitions will be the priority for the Equasens Group in the coming months.
The Group therefore plans to expand the ATOOPHARM training offering to all healthcare professionals it serves and to integrate the technological building block developed by SPEECH2SENSE into all of its business software.
These developments will provide the Group with a differentiating value proposition in its various markets.
The Group confirms that it remains attentive to external growth opportunities and has the financial capacity to achieve them.
Financial calendar: Publication of Q3 2023 revenue on November 9, 2023 (after market).
©2023 Boursier.com